Fifth data and safety monitoring board meeting of the EffiKIR trial recommends continuation without modification
Presentation of IPH4102 rationale and Phase I protocol to be presented at the upcoming EORTC cutaneous lymphoma task force meeting
Upcoming investor conferences
Clearance of co-development and commercialization agreement with AstraZeneca and receipt by Innate Pharma of $250m initial payment
IPC, the comprehensive cancer center of Marseille, and Innate Pharma collaborate on translational research for novel immune checkpoint inhibitors
2015 Half-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
Number of shares and voting rights of Innate Pharma as at June 16, 2015
Number of shares and voting rights of Innate Pharma as at May 18, 2015
Financial update for the first quarter of 2015
Outcome of Annual General Meeting of April 27, 2015
